If your team tackles sample management and/or biomarker operations, don’t miss this year’s SCOPE (Summit for Clinical Operations Executives) conference in Orlando! QuartzBio will be presenting
“From Site to Result: Real-Time Sample Intelligence Unlocked with GenAI” 12:35 PM, Tuesday, February 4, Modernizing Lab, Biomarker & Data Management Operations track
We’ll demonstrate how you can use QuartzBio’s AI-enabled platform to ask questions, get answers, and gain insights across the entire precision medicine data ecosystem, with real-time sample intelligence from point of collection to data generation.
Want to explore our sample intelligence solution in person?
We’re thrilled to be a Gold Sponsor at BiotechX USA, in Philadelphia this September 17-18 — the much-anticipated conference covering precision medicine and digital transformation in biopharmaceutical development. Will we see you there?
Here’s a sneak peek at what you’ll experience when you demo QuartzBio’s AI-enabled Biomarker Intelligence Platform, powered by the first Precision Medicine LLM Ecosystem, at booth #501:
Meet QuartzBio’s AI Virtual Assistant: Transform the way you access, interact with, and extract value from their sample and biomarker data via conversational AI – ask your data a question and get answers in seconds.
Explore integrated sample and biomarker data: Conversationally interact with sample and biomarker data, connected to clinical annotations, across programs. Overcome the challenges of disparate data sources, siloed technologies, and fragmented insights with a unified, AI-enabled ecosystem.
Unlock smarter, faster decisions: Learn how our precision medicine large language model (PM-LLM) ecosystem uses the power of generative AI to facilitate decision-making in areas including patient / dose selection, target identification, and streamlining trial operations.
Example applications and benefits of conversational AI for precision medicine, translational research, biomarker / sample operations and data science teams:
https://www.quartz.bio/wp-content/uploads/2024/08/LinkedIn_BioTechX_1200x1200_D_final.jpg12001200QuartzBio Team/wp-content/uploads/2024/06/quartz-bio.svgQuartzBio Team2024-08-12 15:34:002024-10-09 10:26:50BiotechX USA 2024: Learn how Precision Medicine LLMs enable conversational sample and biomarker intelligence
Ask a question, get an answer, and gain valuable insights across the precision medicine data ecosystem.
Powered by the first ensemble of Precision Medicine Large Language Models (LLMs)
Supercharges the day-to-day work of translational researchers, data scientists, and informatics teams.
Join Bill Hall as he chats with QuartzBio’s Virtual Assistant, conversationally extracting insights in seconds with questions such as:
“Which mutations have highest prevalence at baseline?”
“Which subjects are in the 70th percentile of JAK2 expression at baseline and have stored, consented, baseline samples?”
“What is the correlation of JAK2 and STAT1 expression at baseline across samples?”
You’ll discover QuartzBio’s approach, which employs smart, automated integration of biomarker, sample, and clinical data to create a unified data ecosystem – now amplified with the power of conversational interactions to enable more consumable insights, regardless of your data expertise.
Who should attend:
Translational Scientists Data Science and Bioinformatics Teams R&D Information Technology (IT)
https://www.quartz.bio/wp-content/uploads/2024/08/Linkedin_Webinar-SEPT2024_Empowering-PM-with-Conversational-AI_A.jpg10801080QuartzBio Team/wp-content/uploads/2024/06/quartz-bio.svgQuartzBio Team2024-07-26 19:14:102024-10-09 10:15:50Webinar: Empowering Precision Medicine with Conversational AI — A New Era of Biomarker Intelligence
Here’s a sneak peek at what you’ll experience when you demo QuartzBio’s AI-enabled Biomarker Intelligence Platform, powered by the first Precision Medicine LLM Ecosystem, at booth #15143:
Meet QuartzBio’s AI Virtual Assistant: Transform the way you access, interact with, and extract value from their sample and biomarker data via conversational AI – ask your data a question and get answers in seconds.
Explore integrated sample and biomarker data: Conversationally interact with sample and biomarker data, connected to clinical annotations, across programs. Overcome the challenges of disparate data sources, siloed technologies, and fragmented insights with a unified, AI-enabled ecosystem.
Unlock smarter, faster decisions: Learn how our precision medicine large language models (PM-LLMs) use the power of generative AI to facilitate decision-making in areas including patient / dose selection, target identification, and streamlining trial operations.
Example applications and benefits of conversational AI for precision medicine, translational research, biomarker / sample operations and data science teams:
https://www.quartz.bio/wp-content/uploads/2024/08/QuartzBio-at-ASCO-2024-Precision-Medicine-LLM.jpg10801080QuartzBio Team/wp-content/uploads/2024/06/quartz-bio.svgQuartzBio Team2024-04-30 20:18:472024-08-07 14:37:04ASCO 2024: Learn how Precision Medicine LLMs enable conversational sample and biomarker intelligence
“Harnessing Insights Across Clinical Trials with the Power of Conversation” — a presentation by Tobi Guennel, Ph.D., head of product development and innovation at QuartzBio
Watch the recording of the presentation:
Summary:
Discussions were lively at the “Digitization of Clinical Development & Clinical Trials” symposium at last week’s Bio-IT World conference.
Addressing an audience of biotech and pharma IT and data leaders, QuartzBio’s Tobi Guennel gave a provocative presentation on how deploying generative AI can amplify the ability of precision medicine approaches to accelerate drug development.
“It’s great to have a clinical trials-focused session at Bio-IT World, and being able to share success stories, especially about AI, in this landscape,” said Guennel. “We are firm believers that iteration and collaboration can only improve technology and create new paths for innovation.”
Guennel’s narrative centered around QuartzBio’s Biomarker Intelligence Platform, powered by AI, which allows precision medicine development teams to extract the most value from clinical trial samples and exploratory biomarker data.
“One benefit of natural language understanding capabilities of conversational AI is that a broad range of user personas, with diverse roles and functions, can interact with and extract insights from a unified, singular data ecosystem of sample and biomarker data.
Teams such as data science, translational research, and biosample or biomarker operations can now interrogate a unified data asset using natural language.”
Considerations for developing a large language model (LLM) ecosystem for precision medicine
To build a solid GAI framework to enable our sample and biomarker intelligence products, the QuartzBio team asked themselves:
What LLMs are needed to support our domain and the tasks performed through the components of our products?
How can we integrate these models into a scalable GAI workflow to support user stories and workflows without having to re-invent the wheel as we move from use case to use case?
QuartzBio’s Biomarker Intelligence Platform, powered by AI: An ecosystem of domain- and task-specific small LLMs trained by fine-tuning existing foundational models (FMs). LLMs support the data management layer of the platform, the business intelligence layer to support conversational and prescriptive AI insights, and the overarching navigational AI component to enhance user experience and adoption.
Considerations for developing individual LLMs:
LLM Development
Leverage existing Foundational Models: Start with existing powerful language models that are right-sized.
Fine-Tuning: Customize these models for specific domains and tasks.
Small LLMs: Create smaller, specialized models for targeted applications for improved cost/accuracy.
GAI Integration
Prompt Engineering: Design tailored prompts to guide LLM behavior based on supported tasks.
Leverage RAG: Combine LLMs with retrieval mechanisms for enhanced performance.
User Agents: Implement user-specific agents to optimize model interactions and leverage live data.
Benefits
Precision: Fine-tuned LLMs provide accurate and context-aware responses for specific tasks.
Supporting the entire precision medicine lifecycle
QuartzBio is integrating this GAI framework seamlessly into its Biomarker Intelligence platform to support a broad range of user stories and flows with a suite of SaaS products.
Sponsors are using the platform and products to build an interconnected data asset and, subsequently, draw insights via QuartzBio’s Biomarker Intelligence tools powered by conversational AI.
Sponsors leverage the platform as a force multiplier by creating internal efficiencies. Their teams are free to focus on insight generation rather than data wrangling.
Further, the QuartzBio platform amplifies knowledge by centralizing information and insights and making these easily consumable by a wide range of stakeholders. Ultimately, this increased access to intelligence enables sponsor teams to advance Precision Medicine objectives, such as accelerating patient selection strategies, identifying drug targets, and driving clinical trial efficiency.
Learn more: Watch a demo of QuartzBio’s AI-powered platform
Join the next webinar demonstration of our platform by signing up on our Webinars & Events page! We’ll invite you to our next webinar, and meanwhile you can watch one of our recent demos on demand.
https://www.quartz.bio/wp-content/uploads/2024/08/QB_BIOIT_PRES_Tobi_Followup_04242024.jpg10801080Chandreyee Das/wp-content/uploads/2024/06/quartz-bio.svgChandreyee Das2024-04-23 15:30:242024-10-02 14:53:27AI-Enabled Biomarker Intelligence — QuartzBio at Bio-IT World 2024
Last week, biomarker intelligence leaders from Boston-area R&D organizations got a firsthand look at the powerful predictive and prescriptive intelligence that will soon infuse QuartzBio’s AI Biomarker Intelligence Platform, after sharing common challenges facing data-rich precision medicine clinical programs.
Even though our guests represented organizations that varied in size, number of clinical trials, and therapeutic area, they all shared the challenges of disconnected technology and data ecosystems. Over three million data points are generated per clinical trial and over 70% of that data comes from labs. Sponsor organizations are realizing that they are missing opportunities to advance precision medicine if they do not address their data and technology challenges.
Guest speaker and AI expert, Srivatsan Nagaraja, described the potential of generative AI (GAI) and large language models to overcome these challenges and speed decision-making; not surprisingly, 76% of biopharma companies are investing in AI.
Srivatsan left the audience with two takeaways:
“Generative AI is not going away – and the journey is as important as the destination.”
The journey, in this context, refers to
How the GAI model is trained and prompted – ideally, by subject matter experts and domain-specific knowledge, iteratively improving the value derived from AI
The quality, structure, and format of the underlying data
The QuartzBio team gave a quick demo of their AI-powered Biomarker Intelligence Platform, showing guests how they could get a 360° look around their sample ecosystem in seconds.
We wrapped up the Biomarker Intelligence Summit with a networking happy hour and hands-on exploration stations. Guests interacted with QuartzBio’s conversational AI Virtual Assistant, experiencing how it could help derive valuable insights quickly and easily.
Have a burning question for our team and/or the QuartzBio AI Virtual Assistant?
Key Takeaways from SCOPE Summit for Clinical Operations Executives 2024
Tobi Guennel, PhD, QuartzBio’s Senior Vice President of Product & Chief Architect, energized the Biomarkers & Precision Medicine track at SCOPE 2024 by showing how generative AI can address challenges faced biospecimen and biomarker operations teams, as well as clinical and translational teams, when gathering insights on samples across all parts of a complex biomarker data ecosystem.
Sponsor teams need faster answers from disconnected data streams.
Sponsor teams want more clarity. The current chaotic state of biospecimen management hinders speedy decision-making. Because of the influx of specimen (and their associated data) coming from hundreds of varied locations (in just as many varied formats), teams can feel overwhelmed with the sheer volume of information to manage.
“What’s the status of today’s shipments?” “Where is this sample’s location?” “How is Site 53’s sample collection performance?” “What’s the current turnaround time for genetic testing?”
How is the current system holding businesses back?
Quality data is the foundation of precision medicine but most of this critical data is siloed, inconsistent, and inaccessible. In fact, half of all translational scientists in our industry struggle to access the insights they need to complete their work effectively. Further, many of these scientists report only 60% confidence in the accuracy of this data when manual data entry is considered, and the revenue loss due to data ecosystem challenges is over $31B annually. But, for the companies who can overcome these data and technology ecosystem challenges, the reward is great: these companies are 23x more likely to be profitable than those who cannot.
Generative AI overcomes data challenges
As discussed at the SCOPE Day 1 plenary panel on generative AI, there is now broad awareness of the potential for AI to accelerate drug development. Specifically, we heard how AI is already enabling universal data structuring, harnessing large language models to tackle clinical research tasks, and integrating multimodal data.
Generative AI empowers drug development teams to overcome data and technology ecosystem challenges because it can automate data management tasks and break down data silos, helping businesses gain a holistic view of their operations, and free teams to make more informed decisions, faster. Instead of requiring an extensive understanding of coding and statistical modeling, generative AI now allows users to ask requests in plain language. Ask a question, get an answer.
Generative AI applied to both data management AND business intelligence drives precision medicine at scale
With the AI-enabled Biomarker Intelligence Platform, QuartzBio is giving sponsors a smart and scalable platform for deploying generative AI to enhance decision-making throughout the precision medicine R&D lifecycle. This platform is built on a foundation of high-quality data, because insights mean nothing if you don’t first ensure quality data. QuartzBio’s AI-powered data management tools are tailor-made to streamline data ingestion, QC, and mapping for drug development workflows, helping to improve data quality and reduce errors by leveraging automation to surface data issues to stakeholders.
Layered on these data management tools, the platform contains a suite of business intelligence tools that we call biomarker intelligence tools because they were purpose-built to address the challenges in biomarker-guided drug development. These tools are designed by subject matter experts to improve business agility through data exploration, dashboards, analytics, and reporting.
QuartzBio Biomarker Intelligence Platform
Leveraging AI across the platform makes our data management and business intelligence tools smarter, easier to use and more efficient to configure. To create a true force amplifier and decision accelerator, we’ve built our AI-powered Virtual Assistant. This assistant transforms the way users interact with our platform to shorten the time from having a question to receiving easily consumable information. The Virtual Assistant is your personal guide through our Biomarker Intelligence Platform, allowing you to quickly navigate to the right tool and streamline your data management and business intelligence.
https://www.quartz.bio/wp-content/uploads/2024/02/Tell-me-what-I-dont-know-SCOPE-2024.png619619QuartzBio Team/wp-content/uploads/2024/06/quartz-bio.svgQuartzBio Team2024-02-12 16:41:492024-10-28 15:08:43Tell me what I don’t know: AI-enhanced decisions in biomarker-informed trials
February 11-14, 2024 | Orlando, FL, USA
Curious if an AI-enabled solution is right for your clinical sample management? At this year’s SCOPE (Summit for Clinical Operations Executives) conference we’ll be presenting:
“Tell me what I don’t know: AI-enhanced decisions in biomarker-informed trials” 12:20 PM, Monday February 12, Operationalizing Biomarker & Precision Medicine Trials track
where you’ll learn about deploying generative AI in drug development.
We’ll demonstrate how conversational AI empowers users to extract insights from sample and biomarker information. Additionally, we’ll discuss how predictive features of GAI may enable novel insights by proactively surfacing information instead of passively waiting for input.
Talk to your data to get fast answers across the entire sample lifecycle
Duration: 30 minutes
Sign up to watch the webinar on demand:
What you’ll learn:
Every day, you are pressed to make decisions based on chaotic, disconnected flows of biospecimen status and consent information.
Learn how conversational AI enables you to talk to your biospecimen data. Ask a question, get an answer, and begin your journey from chaos to insight across the entire biospecimen lifecycle.
Join Bill Hall for a demo of our virtual Sample Inventory Management solution, powered by an AI-enabled Biomarker Intelligence Platform and intuitive Virtual Assistant:
Access, interrogate, and conversationally derive valuable insights from sample data across clinical trials
Proactively surface discrepancies and act on trends as they emerge
Gain insights into vendor and site performance
Get answers in seconds on status of sample shipments, testing, stability and expiration
Bill will be chatting with the QuartzBio Virtual Assistant, the intuitive new guide to the QuartzBio platform!
https://www.quartz.bio/wp-content/uploads/2023/12/QuartzBio-Taming-Sample-Chaos-Webinar-Featured-Image.png559559QuartzBio Team/wp-content/uploads/2024/06/quartz-bio.svgQuartzBio Team2023-12-22 15:32:202024-08-23 16:23:56Webinar On Demand: Taming clinical sample chaos with conversational AI
Explore patient biomarker profiles across assays and vendors with a single solution
Duration: 30 minutes
Sign up to watch the webinar:
What you’ll learn:
Biomarkers, when used to guide clinical programs, could mean the difference between success and failure.
But exploratory biomarker data can be a headache to manage. Translational and data science teams struggle with disconnected data flows from specialty labs, sponsor data processing pipelines, and clinical data stores.
Join Bill Hall for a webinar demo of the QuartzBio® enterprise Biomarker Data Management solution.
We’ll show you how to
Generate patient profiles to view tumor burden over course of treatment
Explore multi-marker views of patient profiles
Review ancillary data (e.g. images)
Evaluate patient profiles on a cohort level
Cross-reference biomarker measures across file types; e.g., compare ctDNA profiles of interest with clinical efficacy biomarkers such as immunohistochemistry
Who should attend: Translational Research teams, Biomarker Operations teams, Clinical/Biomarker Data Science teams, Clinical Development teams, Bioinformatics and Computational Biology teams, Office of the CIO/CTO, Data Management teams
